Pneumovax 23 induces type-specific antibodies that enhance opsonization, phagocytosis, and killing of pneumococci by leukocytes and other phagocytic cells. The levels of antibodies that correlate ...
PPSV23, known as Pneumovax 23, was approved by the FDA in 1983. It protects against 23 serotypes of pneumococcal bacteria. It has polysaccharides unique to the serotypes, but they are not attached to ...
Adults 19 years and older who received a previous dose of pneumonia vaccine Prevnar 13 or a complete series of Pneumovax 23.
PNEUMOVAX 23 contains a mixture of inactive parts from 23 of the most common types of pneumococcal bacteria. PNEUMOVAX 23 is a vaccine given to help prevent infections caused by certain types of ...